Monte Rosa Therapeutics, Inc. has initiated a Phase 1 study for MRT-8102, a novel molecular glue degrader targeting the NEK7 protein to treat inflammatory conditions linked to the NLRP3 inflammasome.
(RTTNews) - Monte Rosa Therapeutics, Inc. (GLUE), a clinical-stage biotechnology company, is scheduled to highlight interim clinical results from the ongoing Phase 1 study of MRT-8102, being developed ...
In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results